Wir sind mit live! Mehr erfahren

Fulcrum Therapeutics

FULC

Börsenwert 279 Mio. $

3,65 USD

-0,02

0,54 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

3,65

0,00

0 %

1 Tag

-0,54 %

5 Tage

-3,18 %

1 Monat

-3,69 %

3 Monate

4,29 %

6 Monate

-54,32 %

Seit Jahresbeginn

-66,58 %

1 Jahr

-60,71 %

5 Jahre

-84,16 %

10 Jahre

-72,96 %

Profil: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Mitarbeiter: 55

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 4,5 %

Neutral 93,2 %

Negativ 2,3 %

Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors

New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors

Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights

New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights

Kaplan Fox Investor Alert: Fulcrum Therapeutics, Inc. (FULC) Investigated for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - October 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Kaplan Fox Investor Alert: Fulcrum Therapeutics, Inc. (FULC) Investigated for Possible Securities Law Violations

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - September 30, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations

Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Pending Securities Investigation

New York, New York--(Newsfile Corp. - September 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Pending Securities Investigation

Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors: The Firm is Investigating Possible Securities Law Violations

New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors: The Firm is Investigating Possible Securities Law Violations

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)

BALA CYNWYD, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)

Kaplan Fox Broadens its Investigation of Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Kaplan Fox Broadens its Investigation of Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Learn More About the Firm's Investigation

New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Learn More About the Firm's Investigation

Kaplan Fox Shareholder Alert: Fulcrum Therapeutics, Inc. (FULC) is Under Investigation for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.

Kaplan Fox Shareholder Alert: Fulcrum Therapeutics, Inc. (FULC) is Under Investigation for Possible Securities Law Violations

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt